An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors

Trial Profile

An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Brain cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Feb 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
    • 07 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 Sep 2018.
    • 07 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top